NCT04174716 2026-04-17
VASTUS
Idience Co., Ltd.
Phase 1/2 Completed
Clinical Trials
101 trialsNCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT04072952 2026-04-15
mBC
Arvinas Inc.
Phase 1/2 Completed
NCT05304936 2026-04-15
HCW9218 for Advanced Pancreatic Cancer
ImmunityBio, Inc.
Phase 1/2 Completed
NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
NCT07529613 2026-04-14
T-DXd_HER2Low
National Cancer Center Hospital East
Phase 1/2 Completed
NCT02625480 2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2 Completed
NCT01241734 2026-04-08
RICER
Hackensack Meridian Health
Phase 1/2 Completed
NCT04420884 2026-04-08
iintune-1
Takeda
Phase 1/2 Completed
NCT01022476 2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2 Completed
NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04037254 2026-04-06
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT06238687 2026-04-06
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2 Completed
NCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT02204085 2026-04-03
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
NCT06492304 2026-04-03
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
Phase 1/2 Completed
NCT01242267 2026-04-02
Thal/Mel/Vel
Hackensack Meridian Health
Phase 1/2 Completed
NCT03370276 2026-04-02
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT07505615 2026-04-01
VG-INFUSE Tria
Fudan University
Phase 1/2 Completed
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT00066443 2026-03-27
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT03328026 2026-03-27
Combination Study of SV-BR-1-GM With Retifanlimab
BriaCell Therapeutics Corporation
Phase 1/2 Completed
NCT04801147 2026-03-27
DENDR1
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 1/2 Completed
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT00576979 2026-03-24
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1/2 Completed
NCT04990323 2026-03-24
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
ExCellThera inc.
Phase 1/2 Completed
NCT05046171 2026-03-24
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
University of Rochester
Phase 1/2 Completed
NCT05963997 2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT03709446 2026-03-19
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03745326 2026-03-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03441958 2026-03-18
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Completed
NCT04143711 2026-03-18
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT01615029 2026-03-16
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT03223779 2026-03-12
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT06242691 2026-03-06
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT00797719 2026-03-05
Short Neoadjuvant Hemithoracic IMRT for MPM
University Health Network, Toronto
Phase 1/2 Completed
NCT05214482 2026-03-03
A Study of AK112 in Advanced Malignant Tumors
Akeso
Phase 1/2 Completed